Well characterized biological products, challenging yet rewarding
The presentation emphasizes the importance of developing innovative methods and technologies to support the ecosystem and enhance data workflows. It introduces the concept of a new facility, named "Concept," designed to foster innovation, particularly in Europe. The facility aims to bridge the gap from ideation to pilot-scale production, enabling rapid development and commercialization of new products.
This initiative emerged during the 2021 pandemic, inspired by the swift advancements made by companies like Pfizer and Moderna. The facility focuses on adding value and unlocking potential by providing comprehensive support for various manufacturing processes, ensuring deep data characterization and meaningful knowledge extraction. The goal is to act as gatekeepers to innovation, promoting agility and continual adoption of new technologies to deliver impactful scientific advancements.
Learning points
- Efficiency and Innovation: The necessity to do more with less by adopting and supporting innovative technologies, especially in light of increasing pressure on manufacturing organizations to deliver innovative therapeutics under tighter operating conditions.
Who should attend?
- Researchers and Scientists: Those working in glycomics, proteomics, and related fields who are interested in the latest advancements and methodologies.
- Biotechnology and Pharmaceutical Professionals: Professionals involved in the development and commercialization of therapeutics who are looking for ways to accelerate their processes and enhance innovation.
- Academic and Training Institutions: Institutions focused on bioprocessing research and training that can leverage new technologies and approaches to enhance their programs and facilities.
Presenter: Dr. Jonathan Bones (Prinicipal Investigator - Characterization and Comparability Group, NIBRT)
Jonathan joined Prof. Pauline M. Rudds group at NIBRT in 2007. In 2010 Jonathan was appointed as the ‘John Hatsopoulos Research Scholarship’ at the Barnett Institute of Chemical andBiological Analysis at Northeastern University in Boston, MA, working under the mentorship of Prof. Barry L. Karger investigating new approaches for glycomics and the application of proteomics for a better understanding of mammalian cell bioprocessing. In 2012, Dr Bones returned to NIBRT. His research activities have been internationally recognised through his inclusion on the recently announced Medicine Maker Power List of the top 100 most influential scientists in the field of biopharmaceutical manufacturing and analysis.
